

Supporting information

**Tumor-targeted magnetic micelles for magnetic resonance imaging, drug  
delivery, and overcoming multidrug resistance**

Hui-Qin Liu <sup>1,3,#</sup>, Xi-dong Wu <sup>4,#</sup>, Xue-Wen Fang <sup>5,#</sup>, Yun-Song An <sup>1</sup>, Meng Xia <sup>6</sup>, Xiao-Hua Luo <sup>6</sup>, Jun-Zheng Li <sup>6,\*</sup>, Guan-Hai Wang <sup>2,\*</sup>, Tao Liu <sup>1,\*</sup>

<sup>1</sup> Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.

<sup>2</sup> School of Pharmacy, Guangdong Medical University, Dongguan, 523808, China.

<sup>3</sup> Shantou University Medical College, Shantou, Guangdong 515063, China.

<sup>4</sup> Department of Drug Safety Evaluation, Jiangxi Testing Center of Medical Instruments, Nanchang, 330029, China

<sup>5</sup> Department of Radiology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people's hospital), Dongguan, 523059, China

<sup>6</sup> Department of Otolaryngology-Head and Neck Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China

# The co-first authors contributed equally to this work.

\* E-mail addresses for corresponding authors:

[jzli2002@163.com](mailto:jzli2002@163.com) (Junzheng Li),

[wanguanhai@gdmu.edu.cn](mailto:wanguanhai@gdmu.edu.cn) (Guanhai Wang),

[taoliu18@126.com](mailto:taoliu18@126.com) (Tao Liu)

Tel and Fax:

+86-18928900393(Junzheng Li);

+86-15118359628 (Guanhai Wang);

+86-15627864803(Tao Liu).

## **Contents**

1. Experimental details

## 2. Supporting Figure

## 3. References

### 1. Experimental details

#### 1.1 Determination of IC<sub>50</sub> values for C666-1 cells

C666-1 cells were used as the parent cells in this experiment, the IC<sub>50</sub> value of C666-1 cells needs to be determined first. The IC<sub>50</sub> value of C666-1 was determined by MTT colorimetric assay. The specific experimental procedures are as follows:

1. C666-1 cells in 200 µL of logarithmic growth were seeded on 96-well plates at a cell density of  $1 \times 10^5$  cells per well.
2. After 24 hours of attachment, the old solution was discarded and new DMEM medium (containing 10% FBS) containing different concentrations of docetaxel (10, 20, 30, 40, 50, 60, 70 and 80 µg/mL) was added, and three complex wells were designed.
3. After 48 hours, discard the old solution, add 200 µL new DMEM medium (containing 10% FBS) and 50 µL 5 mg/mL MTT solution, and incubate for 4 hours. After removal of the supernatant, staining was terminated by adding 150 µL DMSO to each well. The absorbance OD value of each well was measured by microplate reader at a wavelength of 490 nm, and the cell survival rate was calculated according to the OD value and the cell survival rate histogram was drawn. The IC<sub>50</sub> value was calculated by Graphpad Prism 8 software to be 17.99 µg/mL. Cell viability was calculated using the following formula:


$$\text{Cell viability (\%)} = \left( \frac{OD_{490\text{sample}}}{OD_{490\text{control}}} \right) \times 100\%$$

#### 1.1.2 Screening of drug-resistant cell lines

The principle of constructing drug-resistant strains is that drugs induce mutations in some genes in cells, resulting in drug resistance, which is a process of natural selection. Exposure of nasopharyngeal carcinoma cells by long-term exposure to low-dose drugs (1, 2):

1. For the screening of C666-1/DOC cells, C666-1 cells in the logarithmic growth phase were cultured in six-well plates at a cell density of  $1 \times 10^6$  cells per well.
2. Docetaxel was added when the cell density reached 70-80%. In the first stage, drug was added at 1/8, 1/4 and 1/2 of the  $IC_{50}$  of parental cells (17.99  $\mu\text{g}/\text{mL}$ ) in order to avoid a large number of cell death at the beginning of drug addition.
3. After 48 hours, the cells were passaged, and if a large number of cells died, the cells were washed twice with PBS buffer before trypsin digestion. The cells were then transferred to clean wells in a new six-well plate for further culture while the cell status was observed.
4. If the density did not grow to 70-80% by the next day, the culture medium was changed and the culture was continued. When cell growth reached 70 to 80%, the same dosing treatment was continued. The procedure was repeated to screen for stable resistant strains.
5. If C666-1 cells can grow normally at a specific concentration and there is basically no cell death, increase the concentration of docetaxel for dosing. Until the cells can grow stably and can be passaged at a specific drug concentration.
6. C666-1 cells were incubated with different concentrations (10, 20, 30, 40, 50, 60, 70 and 80  $\mu\text{g}/\text{mL}$ ) of docetaxel. The absorbance of each well in a 96-well plate was measured by a microplate reader at 490 nm wavelength. The  $IC_{50}$  value was calculated by Graphpad Prism 8 software. At the same time, the survival rate of parental cells treated with docetaxel in this concentration range was compared to check the drug resistance effect. After drug culture, the survival rate of C666-1/DOC cells was statistically different from that of C666-1 cells ( $P < 0.05$ ).
7. In the whole process of adding drugs, the state of cells is the key to culture, and only under the condition of good state can the drug be added for the purpose of drug screening. Finally, C666-1/DOC cells with  $IC_{50}$  value of 43.58  $\mu\text{g}/\text{mL}$  were selected as the drug resistant strain in this study. In order to maintain the drug resistance of C666-1/DOC cells, taking the  $IC_{50}$  concentration of C666-1/DOC as a reference and without significant effect on cell growth, 10  $\mu\text{g}/\text{L}$  docetaxel was added to the DMEM medium during cell culture.

## 2. Supporting Figure



**Fig. S1.** Cell viability of C666-1 cells and C666-1/DOC cells.

## 3. References

- (1) Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B, Liu Y, Liu Y, Yin L, Peng Y, et al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. *Cell Death Dis*, 2017, 8(3): e2659.
- (2) Zhou Z, Zhang L, Xie B, Wang X, Yang X, Ding N, Zhang J, Liu Q, Tan G, Feng D, et al. FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition. *Cancer Lett*, 2015, 363(2): 137–145.